Nümi: The latest figures, news and market research on Nümi

Turnover: ()

Country: France

Biotech company for the production of breast milk by cell culture

Nūmi, the biotech company that invents a cellular substitute for infant milk 09/11/2023

Nūmi is a start-up offering an innovative alternative solution: milk produced by cell culture.
Nūmi's technology involves taking cells from mammary glands, placing them in a culture medium to proliferate, and then recovering the milk produced.
Nūmi is the result of a meeting between Eden Banon-Lagrange, formerly of Entrepreneur First, and Eugénie Pezé-Heidsieck, a specialist in cell biology.
The market for milk produced by cell culture is in its embryonic stage, with Danone as one of the main interested parties.
Nūmi was founded in 2023 and is currently in the R&D phase.
The start-up has raised three million euros in pre-seed funding from Investors Heartcore Capital, HCVC and Financière Saint-James.
Nūmi plans to increase staff to six
The start-up plans to develop a first product for infants aged 0-6 months and sell it to dairy and pharmaceutical manufacturers.
Nūmi plans to move quickly towards industrialization and is considering raising further funds.
The start-up is primarily targeting the American market, due to shorter maternity leave than in Europe and authorities more open to cell biology.

Other companies mentioned:

Other companies mentioned: